Accuracy and cutoff values of delayed heart to mediastinum ratio with 123I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses by Guillaume Lamotte et al.
Lamotte et al. BMC Neurology  (2015) 15:83 
DOI 10.1186/s12883-015-0338-9RESEARCH ARTICLE Open AccessAccuracy and cutoff values of delayed
heart to mediastinum ratio with 123I-
metaiodobenzylguanidine cardiac scintigraphy
for Lewy body disease diagnoses
Guillaume Lamotte, MD1*, Rémy Morello, MD3, Adrien Lebasnier, MD4, Denis Agostini MD, PhD4
and Gilles L. Defer, MD1,2Abstract
Background: Different studies have found diminished cardiac metaiodobenzylguanidine (MIBG) uptake in Lewy
body (LB) related conditions (Parkinson’s disease (PD) and Lewy body dementia (LBD)). However, delayed heart/
mediastinum (d-H/M) ratio diagnostic cutoff points are debated in parkinsonian syndromes.
Methods: We performed a monocentric retrospective analysis on 62 consecutive parkinsonian patients who
underwent an 123I-MIBG scintigraphy, brain imaging and dopaminergic imaging using 123I-Ioflupane single photon
emission computed tomography (SPECT) from 2009 to 2013. The optimal d-H/M ratio was determined from a
Receiver Operating Characteristic (ROC) curve and the sensitivity (Se), specificity (Sp) and likelihood ratios (LR) were
calculated. 42 patients were diagnosed with LB diseases (20 PD, 22 LBD) and 20 patients with other diseases.
Results: 123I-MIBG scintigraphy helped to distinguish PD (p < 0.001) and LBD (p = 0.03) from other diseases. The
optimal d-H/M ratio was 1.48 (0.85 area under the ROC curve). Se and Sp were 83.3 %, and 85 % respectively with
positive and negative LR of 5.5 and 0.2 respectively. Patients with LBD had a lower d-H/M ratio than patients with
PD (result not statistically significant) and a cutoff point at 1.2 could help to differentiate the two diseases. We did
not find any correlation between the d-H/M ratio and clinical or 123I-Ioflupane SPECT data.
Conclusion: According to our population, the d-H/M ratio at 1.48 led to the best performance diagnosis with good
Se, Sp and accuracy. In addition, a d-H/M ratio cutoff at 1.2 could help to differentiate PD from LBD.
Keywords: Sympathetic innervation, Parkinson's disease, parkinsonism, MIBG, Myocardium, Lewy body
dementia, DiagnosisBackground
Supporting clinical diagnosis of a parkinsonian syn-
drome can be challenging, particularly during the initial
phase of the disease. However, improvement of diagnos-
tic accuracy may be important as it influences patient
management, especially if neuroprotective strategies are
developed in the near future. Metaiodobenzylguanidine
(MIBG) is a false adrenergic neurotransmitter analogue
of norepinephrine. 123I-MIBG cardiac scintigraphy is a* Correspondence: guillaumelamotte14@gmail.com
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unless otherwise stated.diagnostic technique to evaluate cardiac sympathetic in-
nervation and noradrenergic post-ganglionic cardiac de-
nervation, a common feature in Parkinson’s disease (PD)
and Lewy body dementia (LBD) [1–5]. It has been sug-
gested that 123I-MIBG cardiac scintigraphy could help to
distinguish parkinsonian syndromes and three recent
meta-analyses suggested very good Se and Sp with this
technique to differentiate Lewy body (LB) diseases from
other neurodegenerative forms of parkinsonism (Fig. 1)
[6–8]. However, there is great variability in technical as-
pects of the procedure between centers and a proposal
for standardizing the technique and the interpretation of
the images has been published recently [9]. The delayedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Planar 123-I MIBG cardiac scintigraphy images. a. 123MIBG cardiac scintigraphy from a patient with multiple system atrophy with normal
cardiac MIBG uptake in delayed image. b. 123MIBG cardiac scintigraphy from a patient with Parkinson’s disease with marked reduction of cardiac
MIBG uptake in delayed image
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tio of the count density for the left ventricle to that for
the upper mediastinum from anterior planar images.
This ratio provides information regarding the uptake,
storage and release of MIBG at nerve endings and is
widely used as a quantitative index of cardiac 123I-MIBG
uptake [9]. The aim of this study was to evaluate the ac-
curacy of the delayed heart/mediastinum (d-H/M) ratio
of 123I-MIBG myocardial scintigraphy that we estab-
lished in a population of 62 consecutive parkinsonian
patients to separate LB diseases from other diagnoses.
Methods
We performed a monocentric retrospective analysis on
62 consecutive parkinsonian patients who underwent an
123I-MIBG scintigraphy, brain imaging and dopami-
nergic imaging using 123I-ioflupane SPECT from January
2009 to March 2013. Evaluations were performed in the
same center outside of a research purpose in order to
help the clinician in patient management. The study was
approved by the Institutional Ethical Committee (North
West III People’s Protection Committee, University Hospital
of Caen, Caen, France). All patients were originally diag-
nosed by a movement disorder specialist between January
2009 and March 2013. In March 2013, we verified that
each patient also fulfilled the current international diagno-
sis criteria for each of the final clinical diagnoses (United
Kingdom Parkinson’s disease Brain Bank Criteria for PD
[10], revised McKeith criteria for LBD [11], criteria from
Gilman et al. in 2008 for multiple system atrophy (MSA)
[12], NINDS-SPSP criteria for progressive supranuclear
palsy (PSP) [13] and criteria proposed by Armstrong et al.
in 2013 for cortico-basal degeneration (CBD) [14]). We
collected clinical data including a detailed battery of
neuropsychological tests when available. Global cognition
was assessed with the Mini Mental State Examination test
(n = 50). Executive functions were assessed with the TMT-A
test time (n = 35), the category fluency test (animals)
(n = 41), the phonemic fluency test (p) (n = 36), and the
Grober and Buschke free recall total score (n = 43).Memory function was assessed with the Grober and
Buschke free and cued recall total scores (n = 43), the Rey
complex figure delayed recall (n = 41), the digit span
forward (n = 37), and the digit span backward (n = 37).
Instrumental functions were assessed with praxis tests
(n = 35) and the Rey complex figure copy (n = 41). When
applicable, the Hoehn and Yahr (H&Y) scale was used to
assess disease severity. In our population, the early stages
of the disease were defined by H&Y stages 1 or 2 or less
than 3 years of evolution of the disease. Patients were di-
vided into four groups regarding the clinical presentation:
akinetic-rigid (AR), tremor-dominant (T), akinetic-rigid
and tremor (ART), and patients with cognitive complaints
with no PD motor core symptoms. We also looked for
treatments that could interfere with the uptake and/or
vesicular storage of MIBG and presence of diabetes as
123I-MIBG myocardial uptake may be affected by various
drugs and cardiac autonomic neuropathy [15, 16].
For all patients 123I-MIBG cardiac scintigraphy was
performed according to the same protocol, which was in
line with the latest recommendations from the European
Cardiovascular Committee [9]. Myocardial infarction
was excluded by rest gated 201Thallium myocardial per-
fusion SPECT and all patients had a normal left ven-
tricular ejection fraction >50 %. At 15 min (early) and
4 h (delayed) after the injection of 370 MBq (10 mCi)
123I-MIBG, anterior planar images were obtained using a
dual-head gamma camera system (SymbiaT2, Siemens)
equipped with a low-energy high-resolution collimator.
A static image was obtained for fixed time (10 min) with
the same acquisition for all patients with a 128×128
matrix. The regions of interest (ROI) were manually
drawn around the heart and the mediastinum. To define
the mediastinum, the landmarks were the apexes of the
lungs and the ROI were drawn on the middle of the two
apexes. The ROIs’ statistics for ratios were provided
from total counts. The tracer uptake was measured
within each region of interest to calculate the d-H/M
ratio. We did a post-hoc analysis after exclusion of
patients with treatments that could interfere with the
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with diabetes [15]. We also collected 123I-ioflupane
SPECT data when available (qualitative interpretation
and semi quantitative analysis).
The sensitivity (Se), specificity (Sp), positive (PPV) and
negative (NPV) predictive values and LR were calcu-
lated. The optimal d-H/M ratio was determined from a
ROC curve. All estimates were calculated with 95 % confi-
dence intervals (95 %IC). Comparisons between groups
were assessed with the Fisher’s exact test. The ANOVA
model (or Mann–Whitney test if the conditions of validity
are not satisfied) was used to compare the means of quan-
titative variables in two independent groups. The relation-
ships between the d-H/M ratio and the clinical,
neuropsychological and 123I-ioflupane SPECT data were
analyzed using the Pearson correlation coefficients. All the
tests were two-tailed and their level of significance (p) was
defined as p < 0.05. IBM®-SPSS® 20.0 for Windows was the
statistical software used.
Results
42 patients were diagnosed with LB diseases (20 PD, 22
LBD) and 20 patients with other diseases (MSA n = 6, PSP
n = 5, CBD n = 1, drug-induced parkinsonism (DIP) n = 2,
Alzheimer disease (AD) n = 2, Perry syndrome n = 1,
others n = 3). Among the group “others”, 1 patient had a
parkinsonian syndrome but was lost to follow-up and 2
patients came to the clinic with mnesic complaints with
no PD motor core symptoms but did not meet the criteria
for AD or LBD. There were no differences in demographic
characteristics between LB diseases and others diagnoses.
The mean follow-up time was 66 months and the mean
delay between onset of symptoms and 123I-MIBG cardiac
scintigraphy was 47.3 months. Table 1 summarizes patient
characteristics.
123I-MIBG scintigraphy helped to distinguish PD
(p < 0.001) and LBD (p < 0.001) from other diseases. As
expected, this technique did not differentiate PD from
LBD (p = 0.7) (Table 2). In our population, the optimal
d-H/M ratio was set at 1.48 with 0.85 area under the
ROC curve (95 %IC 0.745-0.953; p < 0.001) (Fig. 2). Se
and Sp were 83.3 %, and 85 % respectively, PPV and
NPV were 92.1 % and 70.8 % respectively, and positive
and negative LR of 5.5 and 0.2 respectively.
After exclusion of patients with treatments that could
interfere with the uptake and/or vesicular storage of
MIBG and patients with diabetes (5 PD, 12 LBD, 2
MSA, 1 PSP, 1 other), the results were still statistically
significant and 123I-MIBG scintigraphy helped to distin-
guish PD (p < 0.001) and LBD (p < 0.05) from other dis-
eases. The optimal d-H/M ratio after exclusion of these
patients was 1.48 with 0.85 area under the ROC curve
(95 %IC 0.725-0.975; p < 0.001) and diagnostic perfor-
mances were similar with Se and Sp of 87.5 % and 80 %respectively (Fig. 2). There were no significant dif-
ferences between these patients and patients without
any potential pharmacological interaction or with-
out diabetes regarding the clinical presentation and the
123I-MIBG cardiac scintigraphy results. Mean d-H/M ra-
tio was 1.27 +/− 0.21 for the 12 LBD patients who were
excluded and 1.25+/−0.24 for the 10 other LBD patients
(p > 0.05). Mean d-H/M ratio was 1.23+/−0.24 for the
5 PD patients who were excluded and 1.37+/−0.17 for
the 15 other PD patients (p > 0.05).
Fig. 3 shows the distribution of the d-H/M ratio by
diagnoses. Although this was not statistically significant,
patients with LBD had a lower d-H/M ratio than pa-
tients with PD. The mean value of the d-H/M ratio was
1.35 (range: 0.99-1.76) in patients with PD and 1.17
(range: 1.06-1.75) in those with LBD. A cutoff point at
1.2 for the d-H/M ratio could help to differentiate the
two diseases. With this cutoff point 80 % of PD patients
had a d-H/M ratio >1.20 and 80 % of patients with a
d-H/M ratio <1.20 had LBD.
We did not find any significant correlation between
the d-H/M ratio and clinical data including age, disease
duration, disease severity, clinical phenotype and neu-
ropsychological evaluation. We found no significant cor-
relation between the d-H/M ratio and 123I-ioflupane
SPECT data.
Discussion
Cardiac sympathetic innervation was significantly im-
paired in LB related disorders (PD and LBD) in compari-
son to other diagnoses. In our population, the optimal
d-H/M ratio was 1.48 and led to the best performance
diagnosis with good Se, Sp and accuracy. Three recent
systematic meta-analyses have suggested high perfor-
mance diagnosis with this technique to differentiate LB
disorders from other forms of parkinsonism with overall Se
from 88 to 94 % and overall Sp from 82.6 to 91 % [6–8].
Our study suggests similar results. In addition, the d-H/M
ratio at 1.48 is close to 1.43, which was the best cutoff point
defined by a study by Muxi et al. comparing patients in a
Caucasian population with PD with normal age- and sex-
matched subjects [17]. Muxi et al. used the same type of
camera and collimator (Siemens dual-head camera
equipped with a low-energy high-resolution parallel-hole
collimator) as our study, which supports a good interob-
server reproducibility for d-H/M ratio.
Patients with LBD had a lower d-H/M ratio than pa-
tients with PD (result not statistically significant) and a
cutoff point of 1.2 could help to differentiate the two dis-
eases. Suzuki et al. have compared sympathetic myocardial
innervation between LBD and PD and have reported a
lower 123I-MIBG uptake in LBD than in controls or PD
patients [18]. According to the authors, this result could
reflect a greater postganglionic cardiac sympathetic
Table 1 Patient characteristics
All patients PD LBD MSA PSP CBD Others
N 62 20 22 6 5 1 8
Male/female 25/37 10/10 8/14 2/4 3/2 0/1 2/6
Age at diagnosis (y),
mean +/− SD
64 +/− 13.4 56.7 +/− 16.2 69.8 +/− 9.3 60.7 +/− 4.5 64 +/− 9.7 70 68.2 +/− 14.9
Disease duration (mo),
mean +/− SD




47.3 +/− 43.4 65.8 +/− 59.9 35.3 +/− 25.7 47.7 +/− 19.5 48.8 +/− 57 28 35.3 +/− 29.7
AR/T/ART/Non motor 32/5/22/3 6/3/11/0 12/1/8/1 6/0/0/0 3/0/2/0 1/0/0/0 4/1/1/2
H&Y, mean +/− SD 2.4 +/− 1.2 2.4 +/− 1.2 2.3 +/− 1.1 3.6 +/− 1.2 3 +/− 0 4 1 +/− 1.1
L-Dopa-equivalent dose,
mean +/− SD, (N)
407.5 +/− 436.9 (37) 520 +/− 438.2 (16) 260 +/− 374.6 (10) 638.3 +/− 502.4 (5) 840 +/− 378.2 (4) 0 (0) 139.5 +/− 262.9 (2)
DaTSCAN, N 40 11 14 5 3 1 6
Neuropsychological
assessment, N
50 12 21 4 4 1 8
PD, Parkinson’s disease; LBD, Lewy body dementia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBD, cortico-basal degeneration; AR, akinetic-rigid; T, tremor-dominant; ART, akinetic-rigid and













Table 2 Results of 123I-MIBG cardiac scintigraphy with a d-H/M
cutoff at 1.48








*Comparison between LB diseases (PD or LBD) and others
**Comparison between PD and LBD
Fisher exact test
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ology in sympathetic ganglia in LBD compared to PD.
Another hypothesis is the occurrence of transsynaptic
denervation in LBD due to a greater number and wider
distribution of LB in the brain of LBD patients, especially
in the central autonomic control system [18]. Although
the difference was not statistically significant in our popu-
lation, our preliminary data support the finding that LBD
patients could have a lower d-H/M ratio than PD patients,
independent of disease severity. Additional studies are
needed to confirm such a d-H/M ratio difference and
understand the underlying pathophysiology.
Several studies found correlations between myocardial
sympathetic denervation and clinical presentation in PD.
Spiegel et al. and Chung et al. found a significant corre-
lation between myocardial sympathetic denervation and
severity of hypokinesia and rigidity but not with tremor
[19, 20]. However, Chiaravalloti et al. found a correlation
only with tremor [21]. Kim et al. have shown thatFig. 2 ROC curves for the differential diagnosis between LB related disease
a. ROC curve including the 62 patients. b. ROC curve after exclusion of pat
vesicular storage of MIBG and/or patients with diabetescognitive decline in patients with PD was associated with
a greater impairment in myocardial sympathetic dener-
vation [22]. We did not find any correlation between the
d-H/M ratio and clinical or neuropsychological data.
The former could be explained by the heterogeneity and
the low number of patients in our study, and the latter
by the difference in the cognitive tests used and the
definition of cognitive impairment between the studies.
We did not find a relationship between cerebral and car-
diac changes in our PD patients, which supports the results
observed by Raffel et al. in a PET study [23]. However, in a
large homogeneous cohort of PD patients, Spiegel et al.
found a strong correlation between cerebral nigrostriatal
dopaminergic degeneration using 123I-ioflupane SPECT
and myocardial sympathetic denervation [24]. Despite
similar imaging techniques, the size difference between
the two cohorts and heterogeneity of our PD group could
explain the difference in the results between the two
studies. Additional studies considering disease duration
and disease severity are needed to answer this question.
Some studies have suggested that cardiac 123I-MIBG
cardiac scintigraphy could be of limited value in the
diagnosis of LB related disorders in the early stages of
the disease because of a lower Se [25, 26]. In patients
with a PD diagnosis (clinical assessment and dopamine
PET evaluation), Ishibashi et al. found a Se of 53.8 % for
the d-H/M ratio in the H&Y 1 and 2 PD patients [25],
whereas Sawada et al. found a Se of 73.3 % for the d-H/M
ratio in the subgroup with duration of the disease
of ≤3 years [26]. However, in a meta-analysis Orimo et al.s and other diagnoses using the delayed heart to mediastinum ratio.
ients with treatments that could interfere with the uptake and/or
Fig. 3 Delayed Heart to mediastinum (d-H/M) ratio of disorders. The box plots show the median values (mark in the box), 25th percentile (lower
line of box), 75th percentile (upper line of box), minimum value (lower T bar), and maximum value (upper T bar) in each group. The cutoff line is
set at 1.48. PD, Parkinson disease; LBD, Lewy body dementia; MSA, multiple system atrophy; PSP, progressive supranuclear palsy; CBD, cortico-basal
degeneration; DIP, Drug-induced parkinsonism; AD, Alzheimer disease; Perry, Perry syndrome; Others
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and 80.2 %, respectively when PD was limited to early
stages (H&Y 1 and 2) [8]. In our population, there was no
significant difference between early and late stages of the
disease and the accuracy of 123I-MIBG cardiac scintig-
raphy remained the same between the two stages suggest-
ing that 123I-MIBG cardiac scintigraphy may be yet useful
as a diagnostic tool at the early phase of PD.
The main limitations of our study were the hetero-
geneity of our population with only 20 patients with PD,
the relatively low number of subjects and the absence of
histopathologically confirmed diagnoses (except Perry
syndrome). However, all 62 consecutive patients were
seen in a university hospital setting and all files reviewed
by a movement disorder specialist and a nuclear car-
diologist involved in cardiac MIBG imaging. In addition,
final diagnoses were made in agreement with inter-
national diagnosis criteria and the lengthy follow-up
period (66 months) would improved clinical diagnosis
accuracy. The heterogeneity of our population, which
includes 9 different diseases, each with a different pa-
thophysiology, prevents us from making any definitive
conclusions regarding the role of cardiac 123I-MIBG
scintigraphy in each of these diseases individually.
However, cardiac 123I-MIBG scintigraphy clearly de-
tected two diagnostic clusters with good performance
diagnosis: (1) LB related disorders (PD and LBD); and
(2) atypical parkinsonisms without LB (MSA, PSP, DCB,
Perry syndrome), and other forms of dementia such as
AD. Thus, cardiac 123I-MIBG scintigraphy is a potential
diagnostic tool for the clinician that can accurately
distinguish between PD and atypical parkinsonism, andbetween LBD and other forms of dementia. Due to the
retrospective design of the study, we were not able to
verify that potential treatments that could interfere with
the uptake and/or vesicular storage of MIBG were
stopped before the 123I-MIBG cardiac scintigraphy. Des-
pite we can suspect that some of these drugs have de-
creased d-H/M ratio in some of our patients, we can
assume that this potential reduction was non-significant
as the post-hoc analysis we performed after exclusion of
these patients confirmed our initial result with an opti-
mal d-H/M ratio at 1.48.
Conclusion
In this study we have shown, as previously suggested,
that a d-H/M ratio at 1.48 for 123I-MIBG cardiac scin-
tigraphy led to the best performance diagnosis to differ-
entiate LB related disorders (PD and LBD) from other
diagnoses. In addition, a d-H/M ratio cutoff at 1.2 could
help to differentiate PD from LBD. Further prospective
studies in a large number of subjects with parkinsonian
syndromes are needed to confirm our findings and to
help to understand the pathophysiology of LB related
disorders.
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